Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
| ▸ | ELOC | Q15369 | 1/20 | 0.38 |
| ▸ | ELOB | Q15370 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 2/20 | 0.38 |
| ▸ | PGK2 | P07205 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823835 | 0.80 | TSHR (0.40) | TSHRPRSS1PRSS2PRSS3VHL | |
| SCHEMBL29570582 | 0.80 | PGK1 (0.35) | PGK1PGK2DAOMRGPRX4PTGS1 | |
| SCHEMBL20187499 | 0.80 | CA2 (0.52) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL9396256 | 0.78 | TSHR (0.48) | TSHRPRSS1PRSS2PRSS3VHL | |
| SCHEMBL15045345 | 0.78 | TSHR (0.48) | TSHRPRSS1PRSS2PRSS3VHL | |
| SCHEMBL28265171 | 0.77 | CA2 (0.46) | LTA4HCA2PGK1PGK2 | |
| SCHEMBL662302 | 0.76 | PGK1 (0.38) | PGK1PGK2DAOKIF11MRGPRX4 | |
| SCHEMBL41775 | 0.76 | TSHR (0.67) | TSHRPRSS1PRSS2PRSS3VHL | |
| SCHEMBL1659677 | 0.76 | DAO (0.41) | TSHRPGK1PGK2DAOMRGPRX4 | |
| SCHEMBL14533503 | 0.76 | TSHR (0.46) | TSHRPRSS1PRSS2PRSS3VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980401-B1 | PURINE DERIVATIVES, AS NR2B NEGATIVE MODULATORS AND THE USE THEREOF AS MEDICAMENT, IN PARTICULAR FOR TREATING DEPRESSIVE DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2026-01-20 | — | — | US | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| CN-113950478-B | Purine derivatives as NR2B negative modulators and their use as medicaments, in particular for the treatment of depressive disorders | 勃林格殷格翰国际有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| CN-111344291-B | Imidazopyridine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-21 | — | — | US | disclosed |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-21 | — | — | US | disclosed |
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| CN-101835762-A | 2-aminooxazole derivatives as TRPV antagonists useful for the treatment of pain | ABBOTT LAB | 2010-09-15 | — | — | CN | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | TSHR 3729/4885PRSS1 1282/4885PRSS2 2977/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | TSHR 1495/4885PRSS1 2819/4885PRSS2 3588/4885 |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | MBOAT4, GIPR, MTTP | TSHR 16/4885PRSS1 1802/4885PRSS2 1492/4885 |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | TSHR 828/4885PRSS1 1290/4885PRSS2 1556/4885 |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2C, GRIN3A, GRIN1 | TSHR 413/4885PRSS1 3374/4885PRSS2 4215/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PRSS1 2995/4885PRSS2 3756/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | TSHR 1412/4885PRSS1 2995/4885PRSS2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.